{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "HKD", "exchange": "HKG", "shortName": "AKESO", "longName": "Akeso, Inc.", "messageBoardId": "finmb_660797233", "market": "hk_market", "marketState": "CLOSED", "earningsTimestamp": 1682605019, "earningsTimestampStart": 1682605019, "earningsTimestampEnd": 1682605019, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -1.63, "epsForward": -1.45, "sharesOutstanding": 841057024, "bookValue": 3.134, "fiftyDayAverage": 42.726, "fiftyDayAverageChange": -0.1760025, "fiftyDayAverageChangePercent": -0.00411933, "twoHundredDayAverage": 35.4474, "tradeable": false, "cryptoTradeable": false, "exchangeTimezoneName": "Asia/Hong_Kong", "exchangeTimezoneShortName": "HKT", "gmtOffSetMilliseconds": 28800000, "esgPopulated": false, "regularMarketChangePercent": -2.9646506, "regularMarketPrice": 42.55, "regularMarketChange": -1.2999992, "regularMarketTime": 1683878916, "regularMarketDayHigh": 45.5, "regularMarketDayRange": "42.4 - 45.5", "regularMarketDayLow": 42.4, "regularMarketVolume": 3108000, "regularMarketPreviousClose": 43.85, "bid": 42.5, "ask": 42.6, "fullExchangeName": "HKSE", "financialCurrency": "CNY", "regularMarketOpen": 45.05, "averageDailyVolume3Month": 5429113, "averageDailyVolume10Day": 2599340, "fiftyTwoWeekLowChange": 30.15, "fiftyTwoWeekLowChangePercent": 2.4314516, "fiftyTwoWeekRange": "12.4 - 52.6", "fiftyTwoWeekHighChange": -10.049999, "fiftyTwoWeekHighChangePercent": -0.19106463, "fiftyTwoWeekLow": 12.4, "fiftyTwoWeekHigh": 52.6, "twoHundredDayAverageChange": 7.1026, "twoHundredDayAverageChangePercent": 0.20037013, "marketCap": 36276641792, "forwardPE": -29.344826, "priceToBook": 13.576898, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "averageAnalystRating": "1.6 - Buy", "firstTradeDateMilliseconds": 1587691800000, "priceHint": 3, "symbol": "9926.HK"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "No. 6, Shennong Road", "address2": "Torch Development Zone", "city": "Zhongshan", "zip": "528437", "country": "China", "phone": "86 76 0898 73998", "fax": "86 76 0898 73900", "website": "https://www.akesobio.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Akeso, Inc., a biopharmaceutical company, researches, develops, manufactures, and commercializes therapies. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer (GC), gastroesophageal junction (GEJ) cancer, ESCC, hepatocellular carcinoma (HCC), small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), pancreatic cancer, and solid tumors; and AK112, a PD-1/VEGF bi-specific antibody to treat NSCLC, triple-negative breast cancer (TNBC), head and neck cancer, HCC, colorectal and ovarian cancer, and solid tumors. It is also developing AK105, a PD-1 monoclonal antibody to treat classic Hodgkin's lymphoma (R/R cHL), NSCLC, NPC, HCC, SCLC, thyroid cancer, mesothelioma and thymic cancer, ESCC, UC, GC, GEJ, cholangiocarcinoma, neuroendocrine tumor, and mismatch repair deficient solid tumor; AK117, a CD47 monoclonal antibody to treat myelodysplastic syndrome, acute myeloid leukemia, GC, GEJ, ESCC, HNSCC, CRC, TNBC, and solid tumors/lymphoma; AK119, a CD73 monoclonal antibody for treating solid tumors and NSCLC; and AK109, a VEGFR-2 monoclonal antibody to treat GC, GEJ, NSCLC, HCC, and solid tumors. In addition, the company develops AK102, a PCSK9 monoclonal antibody to treat hypercholesterolemia and mixed hyperlipidemia; AK101, an IL-12/IL-23 monoclonal antibody to treat moderate-to-severe psoriasis and ulcerative colitis; AK111, an IL-17 monoclonal antibody to treat moderate-to-severe psoriasis and ankylosing spondylitis; and AK120, an IL-4R monoclonal antibody to treat moderate-to-severe atopic dermatitis. Further, its preclinical product includes AK127, a TIGIT monoclonal antibody to treat solid tumors; and AK115, a NGF monoclonal antibody. The company has collaboration agreements with Pfizer Pharmaceuticals; AstraZeneca Pharmaceuticals; Summit Therapeutics Inc.; and Shenzhen Chipscreen Biosciences Co., Ltd. Akeso, Inc. was founded in 2012 and is headquartered in Zhongshan, the People's Republic of China.", "fullTimeEmployees": 2341, "companyOfficers": [{"maxAge": 1, "name": "Dr. Yu  Xia Ph.D.", "age": 55, "title": "Founder, CEO, Pres & Chairwoman", "yearBorn": 1967, "fiscalYear": 2021, "totalPay": {"raw": 1021130, "fmt": "1.02M", "longFmt": "1,021,130"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Baiyong  Li Ph.D.", "age": 53, "title": "Co-Founder, Exec. VP, CSO & Exec. Director", "yearBorn": 1969, "fiscalYear": 2021, "totalPay": {"raw": 606341, "fmt": "606.34k", "longFmt": "606,341"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Zhongmin  Wang Ph.D.", "age": 53, "title": "Co-Founder, Sr. VP & Exec. Director", "yearBorn": 1969, "fiscalYear": 2021, "totalPay": {"raw": 487665, "fmt": "487.67k", "longFmt": "487,665"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Yu  Xia Ph.D.", "age": 51, "title": "Sr. VP & Exec. Director", "yearBorn": 1971, "fiscalYear": 2021, "totalPay": {"raw": 577392, "fmt": "577.39k", "longFmt": "577,392"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Peng  Zhang Ph.D.", "title": "Co-Founder & Sr. VP", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Xinfeng  Zhang", "title": "Sr. VP", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Wenjun  Shi", "title": "Sr. VP", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Mingxiu  Hu Ph.D.", "title": "Sr. VP", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Wai Yan  Leung", "title": "Company Sec.", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1640908800, "maxAge": 86400}}], "error": null}}